Growth of children with hypochondroplasia treated with growth hormone for up to three years.
Hypochondroplasia is a skeletal dysplasia characterised by poor childhood growth and an inadequate pubertal growth spurt. 31 children with a radiological diagnosis of hypochondroplasia have been treated for up to 3 years with recombinant human growth hormone, mean dose 17.9 U/m2/week as daily subcutaneous injections. Mean pre-treatment height velocity standard deviation score (SDS) was -0.51; this increased to +1.58 after 1 year of treatment. This improvement diminishes over the next 2 years. The effect on final height remains unknown. There was a considerable variation in clinical response within the group treated.
Bridges
N A
NA
Middlesex Hospital, London, UK.
Hindmarsh
P C
PC
Brook
C G
CG
D000293:Adolescent; D001827:Body Height; D001848:Bone Diseases, Developmental / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D013006:Growth Hormone